Recruiting
EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer
In this study, the investigators hypothesize that a high dose of post-workout protein after each exercise session will have greater improvements in changes in body composition, including muscle mass and percent body fat versus a workout alone.
ClinicalTrials.gov IDNCT07704476
PhaseNA
Enrollment40
SponsorAllegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Age20 Years – 89 Years
SexFEMALE
Conditions studied
Cancer, Breast Cancer
About this study
In this study, the investigators hypothesize that a high dose of post-workout protein after each exercise session will have greater improvements in changes in body composition, including muscle mass and percent body fat versus a workout alone.
Interventions
- Dietary Supplement: Whey protein (60 grams) — 60 grams of whey protein
- Other: No protein — 0 grams of whey protein
Primary outcomes
- Determine changes in pounds of muscle and fat mass after each exercise regimen (Baseline and at program completion (within 4 weeks of exercise completion))
Eligibility information
Inclusion Criteria:
1. Age 20-89 years
2. Women prescribed exercise as a SOC
3. Women with a biopsy proven diagnosis of ductal carcinoma in situ (DCIS) or invasive carcinoma of the breast
4. Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.
5. Women with \> 3 months of resistance training experience under expert guidance by a CSCS
6. Must be able to read and understand English and consent for themselves.
Exclusion Criteria:
1. Any current treatment with cytotoxic chemotherapy for breast cancer
2. Inability to safely engage in group sessions of resistance training as deemed by study PI
3. Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training
4. Beta blocker or GLP-1 inhibitor medications
5. Pregnant women
6. Males
7. Lactose intolerance
8. Cow's milk or whey protein allergy
Study locations
- AHN Allegheny General Hospital, Pittsburgh, Pennsylvania 15212 United States
- AHN Allegheny General Hospital, Pittsburgh, Pennsylvania 15212 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-01.